Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.

Nature medicine | 2015

Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (∼2%) engaged in the cell cycle in the first year of life. In embryonic life and after early childhood, beta cell replication is barely detectable. Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts. Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo. Here, using a high-throughput small-molecule screen (HTS), we find that analogs of the small molecule harmine function as a new class of human beta cell mitogenic compounds. We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation. Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy. Enhancing the potency and beta cell specificity of these compounds are important future challenges.

Pubmed ID: 25751815 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: R-01 DK55023
  • Agency: NIDDK NIH HHS, United States
    Id: R-01 DK077096
  • Agency: NIDDK NIH HHS, United States
    Id: R-01 DK065149
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK067351
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK055023
  • Agency: NIDDK NIH HHS, United States
    Id: U01 DK089538
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK065149
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK105015
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK020541
  • Agency: NIDDK NIH HHS, United States
    Id: P60 DK020541
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK077096
  • Agency: NIDDK NIH HHS, United States
    Id: U-01 DK089538
  • Agency: NIDDK NIH HHS, United States
    Id: R-01 DK067351

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HCT 116 (tool)

RRID:CVCL_0291

Cell line HCT 116 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Hep-G2 (tool)

RRID:CVCL_0027

Cell line Hep-G2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

WI (tool)

RRID:RGD_13508588

Rattus norvegicus with name WI from RGD.

View all literature mentions

HEK293-A (tool)

RRID:CVCL_6910

Cell line HEK293-A is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions